Gland Pharma Limited (NSE:GLAND)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Pharmaceuticals	64.31B	56.17B	56.65B	36.25B	44.01B
Total	64.31B	56.17B	56.65B	36.25B	44.01B

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
USA	34.21B	27.40B	26.88B	20.91B	23.33B
Europe	14.04B	10.23B	10.53B	1.87B	2.40B
Canada, Australia and New Zealand	2.27B	-	-	-	-
India	2.67B	4.77B	5.88B	5.55B	8.80B
Rest of World (ROW)	11.12B	11.38B	11.82B	6.89B	8.48B
Canada	-	1.57B	890.27M	794.90M	829.19M
Australia	-	742.94M	626.45M	218.24M	170.87M
New Zealand	-	77.23M	28.17M	10.86M	-
Total	64.31B	56.17B	56.65B	36.25B	44.01B

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 31, 2026

Data Sources Report a data error